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Summary
Objective: Pharmacokinetic data on glucosamine are scant, limiting the understanding of glucosamine sulfate mechanism of action in support
of its treatment effects in osteoarthritis. This study investigated the oral pharmacokinetics and dose-proportionality of glucosamine after
administration of the patented crystalline glucosamine sulfate in man.
Methods: Twelve healthy volunteers received three consecutive once-daily oral administrations of glucosamine sulfate soluble powder at the
doses of 750, 1500, and 3000 mg, in an open, randomised, cross-over fashion. Glucosamine was determined in plasma collected up to 48 h
after the last dose by a validated Liquid Chromatography method with Mass Spectrometry detection. Pharmacokinetic parameters were
calculated at steady state.
Results: Endogenous plasma levels of glucosamine were detected (10.4e204 ng/ml, with low intra-subject variability). Glucosamine was
rapidly absorbed after oral administration and its pharmacokinetics were linear in the dose range 750e1500 mg, but not at 3000 mg, where the
plasma concentrationetime proﬁles were less than expected based on dose-proportionality. Plasma levels increased over 30-folds from
baseline and peaked at about 10 mM with the standard 1500 mg once-daily dosage. Glucosamine distributed to extravascular compartments
and its plasma concentrations were still above baseline up to the last collection time. Glucosamine elimination half-life was only tentatively
estimated to average 15 h.
Conclusions: Glucosamine is bioavailable after oral administration of crystalline glucosamine sulfate, persists in circulation, and its
pharmacokinetics support once-daily dosage. Steady state peak concentrations at the therapeutic dose of 1500 mg were in line with those
found to be effective in selected in vitro mechanistic studies. This is the only glucosamine formulation for which pharmacokinetic, efﬁcacy and
safety data are now available.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Glucosamine sulfate was found to be effective in controlling
osteoarthritis (OA) symptoms in several clinical studies1e3.
In particular, two randomised, placebo-controlled, double-
blind trials of 3-year duration in knee OA patients, showed
that this symptom-modifying effect is sustained over long-
term treatment courses4,5. Moreover, both studies indicated
that the drug also has a structure-modifying effect, as
assessed by measurement of joint space narrowing on
standardised plain radiographs4,5 by a valid technique6 and
consistently within studies and patient populations7.
However, the mechanism of action by which glucosamine
sulfate exerts these clinical effects has not been fully
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Received 31 March 2005; revision accepted 15 July 2005.10elucidated. A major problem in this respect has been the
limited knowledge about glucosamine pharmacokinetics
after systemic and especially oral administration of glucos-
amine sulfate, due to the lack of suitable bioanalytical
methods able to determine with sufﬁcient sensitivity and
speciﬁcity the compound concentrations in biological
ﬂuids8. Outcries from the medical community have recently
focussed the attention on this limitation9. In fact, it is
currently unclear how much of the unchanged compound
reaches the systemic circulation and thus the possible
biological target within the joint, after exogenous adminis-
tration. The determination of the amounts of drug reaching
the systemic circulation is further complicated by the fact
that glucosamine is a normal constituent of the extracellular
matrix of mammalian articular cartilage and synovial ﬂuid10,
and therefore endogenous concentrations of glucosamine
may be present in blood as a result of this and other
connective tissue turnover. Another currently unaddressed
issue regards the persistence of the drug in the circulation
after dosing, to ensure adequate exposure during treatment
and optimal administration intervals. Finally, the dose-
proportionality of glucosamine pharmacokinetics is also41
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oral doses other than the standard 1500 mg/day glucos-
amine sulfate dosage used in most clinical studies.
Besides its relevance for the understanding of glucos-
amine biological mechanisms, the lack of sensitive and
speciﬁc bioanalytical methods made impossible so far to
test the bioequivalence of different glucosamine formula-
tions, thus creating a major public health concern. In fact,
the patented crystalline glucosamine sulfate 1500 mg once-
a-day soluble powder preparation used here and in the
most relevant clinical trials4,5 is a prescription drug in most
European and extra-European countries, whereas the
Dietary Supplement Health and Education Act of 199411
favoured the appearance on the dietary supplement market
in the USA and other countries of several undocumented
glucosamine salts (e.g., hydrochloride), derivatives (e.g.,
N-acetyl-glucosamine), or dosage forms and regimens.
Besides the questionable active ingredient content of these
uncontrolled commercially available supplements12, when
other salts, formulations and/or daily regimens have been
used in clinical trials, the results have not been favoura-
ble13e16, casting doubts not only on the several confound-
ers and problematic study design for some of these trials,
but also on possible suboptimal bioavailability of the
preparations used17.
Our group has been involved in early efforts to elucidate
the pharmacokinetics and metabolism of oral glucosamine
sulfate in rats, dogs and humans, using 14C-labelled
glucosamine8. Although these studies provided compelling
information about the absorption, distribution and elimina-
tion of radioactivity, they were not able to differentiate the
unchanged drug from its metabolites and/or degradation
products. When tentative speciﬁc methods for the de-
termination of glucosamine in human plasma were de-
veloped, they were not sensitive enough to monitor the
plasma concentration of the unchanged compound after
oral administration of therapeutic doses8,18.
Other authors have recently investigated the pharmaco-
kinetics of some form of oral glucosamine in rats19, dogs20,
and horses21. Due to the high limit of quantitation (LOQ) of
the assays employed, they had to use doses much higher
than those currently used in humans, whose relevance to
the treatment of OA is unknown. More recently, the synovial
ﬂuid and serum concentrations of glucosamine have been
determined in adult female horses following treatment with
oral and intravenous glucosamine at clinically relevant
doses (20 mg/kg), with reasonable assay sensitivity22.
With the availability of hyphenated bioanalytical methods
such as Liquid Chromatography with Mass Spectrometry
detection (LCeMS/MS), it is now possible to accurately and
speciﬁcally determine a large variety of drugs in biological
ﬂuids after administration of therapeutic doses. We recently
developed and validated a sensitive LCeMS/MS method for
the determination of unchanged glucosamine in human
plasma. Due to the low LOQ obtained, the method is able to
determine possible endogenous plasma concentrations of
glucosamine. In the present study, therefore, glucosamine
plasma levels were determined before and after adminis-
tration of increasing oral doses of crystalline glucosamine
sulfate, with the aim to investigate glucosamine endoge-
nous concentrations and whether unchanged glucosamine
reaches the systemic circulation after oral administration, in
amounts that are pharmacologically relevant and dose-
proportional. The study design was selected to mimic the
conditions found during the therapeutic use of glucosamine
in OA patients. In addition, the study allowed to assess
glucosamine pharmacokinetics, including drug persistencein the circulation and the inference about its distribution into
extravascular compartments.
Method
SUBJECTS
Twelve healthy Caucasian volunteers (six males and six
females) were enrolled in the present study. A complete
medical history was obtained from each volunteer. They
were considered healthy at screening based on physical
examination including vital signs recording and routine
laboratory tests on blood and urine.
Subjects were non- or mild smokers %10 cigarettes/day
and drank %5 cups of xanthine-containing beverages
(coffee/tea) per day. They understood and signed the
Informed Consent Form.
STUDY DESIGN
The study protocol and related material were approved by
the Local Ethics Committee of the S. Orsola-Malpighi
Hospital in Bologna, Italy. The study was carried out in
accordance with the current revision of the Declaration of
Helsinki concerning medical research in humans, and with
current Good Clinical and Laboratory Practice Guidelines
(USA and EU).
This was a randomised, open, cross-over design study,
to investigate the dose-proportionality of glucosamine
pharmacokinetics after repeated oral administration of the
patented crystalline glucosamine sulfate formulation at the
once-a-day doses of 750, 1500, and 3000 mg for 3
consecutive days, i.e., the time needed to reach steady
state conditions based on pilot experiments. The possible
presence of endogenous glucosamine in plasma makes
mandatory a multiple dose, steady state pharmacokinetic
study to allow for homeostatic adjustments. This makes
possible to measure the net increase in plasma concen-
trations afforded by exogenous administration23,24. Crystal-
line glucosamine sulfate (Dona, Viartril-S, Xicil or other
trademarks by the Rottapharm Group, Monza, Italy and
Rotta Pharmaceuticals Inc. Wall, NJ) is a deﬁned, pure and
stable substance in which glucosamine, sulfate, chloride
and sodium ions are present in stoichiometric ratios of
2:1:2:2. Doses are deﬁned in relation to the net content in
glucosamine sulfate. The subjects received each of the
three selected dose levels in three different study periods
whose order was randomised according to a Williams
variance-balanced design for three formulations25. Drug
treatment consisted of three consecutive once-daily admin-
istrations of crystalline glucosamine sulfate formulated as
an oral soluble powder presented as a sachet, under fasting
condition and dissolved in 240 ml of water. The three study
periods were separated by a washout of at least 3 days
after the last blood collection (48 h post-dosing) on each
dosing period. Thus, the minimum washout period observed
in the present study between two different dose levels was
5 days. Fasting was maintained from the evening before
and up to 4 h after drug intake, when a light meal was
served consisting of 40 g of boiled rice with 10 g of butter
and 10 g of parmesan cheese, 150 g of chicken, 50 g of
bread, 1 stowed apple (150 g), 200 ml of mineral water. The
meal provided a total of 584 calories (26.4% proteins,
19.4% lipids, and 54.2% glucides). After this light meal and
up to 48 h after drug intake, the food and ﬂuid intake of the
volunteers was monitored to ensure adherence to the
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was collected from the antecubital vein by indwelling
catheters into heparinised tubes before (0 h) and 0.25,
0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 h after the
third and last dose. Blood was also collected before the ﬁrst
and second drug administrations. Aliquots of plasma
(obtained by blood centrifugation at 2000! g at 4(C) were
stored at 20(C pending analysis.
Safety and tolerability were monitored throughout the
study by adverse events recording and by repeating all the
screening procedures at a follow-up visit carried out within 7
days after the study end.
BIOANALYSIS
Glucosamine plasma concentrations were determined by
LCeMS/MS. Brieﬂy, plasma samples (1 ml) were added
with the internal standard (13C-glucosamine) at a ﬁnal
concentration of 250 ng/ml and subjected to a liquid/liquid
extraction by the addition of 1 ml of acetonitrile. The
samples were then stirred on a vortex and centrifuged at
2000! g for 20 min. The supernatants were transferred
into injection vials and a 20 mL sampling volume was
injected into the LCeMS/MS instrumentation. Separation
was achieved using a mixture of acetonitrile and water as
the mobile phase in a gradient mode on an Alliance system
2690 model (Waters). This system was equipped with a
Shodex Asahipak NH2P-50G 2D column (150 mm!
2.0 mm internal diameter (ID); particle size: 5 mm) ﬁtted
with a Shodex Asahipak NH2P-50G 2D (30 mm! 2.0 mm
ID; particle size: 5 mm) guard column. The high performance
liquid chromatography system was connected to an API
2000 (Applied Biosystems) MS/MS instrument operating in
the positive ion mode. Quantitative determination of
glucosamine was performed in the Multiple Reaction
Monitoring mode to follow the transitions 180/ 72 for
glucosamine and 181/ 73 for 13C-glucosamine. Calibra-
tion curves were generated using calibration samples
obtained from glucosamine free plasma spiked with
glucosamine at concentrations ranging from 6.25 ng/ml
(the LOQ of the method, corresponding to 0.03 mM based
on a glucosamine molecular weight of 179.17 as a free
base) upward. Recovery was calculated using six replicate
analyses at three concentrations within the calibration curve
and averaged 92.4%, 101.1% and 98.4%, respectively. The
overall recovery was, therefore, 97.3%. The assay precision
(RSD%) calculated as mean experimental concentration/
standard deviation! 100 and accuracy (BIAS%) calculated
as (mean experimental concentration theoretical concen-
tration)/theoretical concentration! 100 were assessed
both intra- and inter-day using three concentration levels
within the calibration range analysed in six replicates. The
assay precision ranged from 1.5% to 13.9%. Its accuracy
ranged from 0.7% to 18.4%. At the LOQ the precision
ranged from 4.7% to 13.9% and the accuracy from 13.2%
to 18.4%.
The method was validated according to current guide-
lines including bench top, long-term and repeated freeze/
thawing cycles stabilities, as well as 1:10 v/v dilution with
blank human plasma.
PHARMACOKINETIC ANALYSIS
Glucosamine plasma concentrations vs time proﬁles
were analysed using the Kinetica 2000 software version
4.2 (Innaphase, Philadelphia, USA) by standard non-
compartmental methods. Possible concentrations ofendogenous glucosamine determined at baseline were
subtracted from the concentrations determined in all sub-
sequent samples collected from the same individual in the
same treatment period. Subtraction of endogenous levels of
a substance that is also administered exogenously is
requested by current guidelines23,24. Together with a multi-
ple dose study design to allow for homeostatic adjustment,
this ensure the estimation of the net increase in the
circulating levels of glucosamine afforded by the oral
administration of crystalline glucosamine sulfate.
Maximum plasma concentrations at steady state (Css,
max) and the corresponding times (Tmax) were taken directly
from the raw data. At steady state, the area under the
plasma concentrationetime curve within a dosing interval
(AUCss) and up to the last time at which the glucosamine
concentration was measurable (AUCt) were calculated
using the mixed log-linear trapezoidal rule. Glucosamine
plasma concentrations determined before the second and
third drug administrations and 24 h after the third and last
drug administration (day 4), denoted as Cmin, day 2, Cmin, day 3
and Cmin, day 4, respectively, were taken from the raw data in
order to asses the time to steady state. Glucosamine
elimination half-life was only tentatively estimated based
on the time to reach steady state conditions26.
STATISTICAL ANALYSIS
Analysis of variance (ANOVA) after log-transformation
was used to assess any gender or period effect on
glucosamine baseline levels, i.e., comparing basal concen-
trations between males and females and among the three
different treatment periods. In addition, the possible
carryover effect was also included as a factor in the
General Linear Model (GLM) ANOVA for the Williams
variance-balanced design conducted on the pharmacoki-
netic parameters compared across doses (see below).
Investigation of dose-proportionality of glucosamine phar-
macokinetics was one of the objectives of the present
study, i.e., to assess that the increase in plasma levels is
directly related and proportional to the increase in the drug
dose. In case of dose-proportional, and thus linear
pharmacokinetics, a doubling of the dose produces
a doubling of the plasma concentrations. To test the
dose-proportionality of glucosamine pharmacokinetics, the
relevant pharmacokinetic parameters Css, max, AUCss, and
AUCt, determined at the three dose levels were normalised
to the dose of 1 mg, and subjected to the above mentioned
GLM-ANOVA with Tukey HSD test for multiple comparisons
after log-transformation with dose as factor. Presence of
any gender differences in these parameters was also
assessed by ANOVA after log-transformation. Tmax were
compared by the non-parametric KruskalleWallis test
without log-tranformation or dose adjustment. To assess
the time to steady state the Cmin, day 2, Cmin, day 3 and Cmin,
day 4 values were pair-wise compared by paired t test.
P! 0.05 was taken as statistically signiﬁcant in all tests.
Results
The subject demographic characteristics are reported in
Table I, grouped by gender. All subjects were young healthy
volunteers, with normal body mass index (BMI).
Endogenous glucosamine was detected in the plasma of
all subjects (Table II). Baseline plasma levels ranged
between 10.4 and 204.0 ng/ml (corresponding to 0.06
and 1.1 mM, respectively), i.e., with a high degree of
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Subject demographic characteristics
Randomisation no. (with treatment order) Age (years) Height (cm) Weight (kg) BMI (kg/m2)
Women
1 (750, 3000, 1500 mg) 27 160 52 20.3
2 (1500, 750, 3000 mg) 26 160 50 19.5
4 (750, 1500, 3000 mg) 23 162 52 19.8
6 (1500, 3000, 750 mg) 23 153 49 20.9
9 (3000, 1500, 750 mg) 23 150 50 22.2
12 (750, 3000, 1500 mg) 31 165 69 25.3
MeanGSD 25.5G 3.2 158G 5.7 53.7G 7.6 21.3G 2.2
Range 23e31 150e165 49e69 19.5e25.3
Men
3 (3000, 1500, 750 mg) 31 172 80 27.0
5 (3000, 750, 1500 mg) 38 163 63 23.7
7 (3000, 750, 1500 mg) 24 173 65 21.7
8 (1500, 3000, 750 mg) 26 185 75 21.9
10 (750, 1500, 3000 mg) 40 168 70 24.8
11 (1500, 750, 3000 mg) 30 174 65 21.5
MeanGSD 31.5G 6.4 172.5G 7.3 69.7G 6.7 23.4G 2.2
Range 24e40 163e185 63e80 21.5e27.0
Overall
MeanGSD 28.5G 5.7 165G 9.7 61.7G 11 22.4G 2.3
Range 23e40 150e185 49e80 19.5e27.0inter-subject variability, especially within women although it
appeared that there were no signiﬁcant gender differences.
However, analysis of baseline levels before the three
treatment periods revealed a low degree of intra-subject
variability since the concentrations before each treatment
period were very similar for each subject after the
appropriate washout. Indeed, there were no signiﬁcant
differences between periods (Table II). Even though the
endogenous glucosamine concentrations were much lower
compared with those determined after administration of
glucosamine sulfate at all doses and they were similar for
Table II
Baseline glucosamine levels in plasma (ng/ml), before each
treatment period
Randomisation no. Period I Period II Period III
Women
1 45.3 51.2 89.8
2 75.3 39.9 46.0
4 26.2 23.6 10.4
6 54.8 64.7 204.0
9 107.2 41.0 95.6
12 56.2 53.0 44.3
MeanGSD 60.8G 27.8 45.6G 14.1 81.7G 67.8
Range 26.2e107.2 23.6e64.7 10.4e204.0
Men
3 31.9 39.7 33.2
5 41.9 47.0 39.6
7 47.9 50.2 61.0
8 51.2 79.5 25.6
10 63.6 51.3 42.0
11 61.4 54.2 70.2
MeanGSD 49.7G 11.9 53.7G 13.6 45.3G 17.0
Range 31.9e63.6 39.7e79.5 25.6e70.2
Overall
MeanGSD 55.2G 21.2 49.6G 13.8 63.5G 50.8
Range 26.2e107.2 23.6e79.5 10.4e204.0each subject at the start of the three treatment periods, the
baseline subtraction was applied as described since it
represents a conservative approach.
Through concentrations, i.e., those obtained 24 h after
the ﬁrst (Cmin, day 2) and second (Cmin, day 3) dose, increased
over baseline as described in Table III. Within each dose
level, the Cmin, day 3 was not signiﬁcantly different from the
concentration detected 24 h after the third and last
administration (Cmin, day 4), indicating that glucosamine
pharmacokinetics were at steady state with the third
glucosamine sulfate oral intake.
Figure 1 shows the baseline-subtracted average plasma
concentration vs time proﬁles with each of the three once-
daily doses of glucosamine sulfate at steady state. It
appears that glucosamine is rapidly absorbed and available
to the systemic circulation after oral administration. Steady
state mean peak concentrations were achieved 3e4 h after
administration of each dose (median Tmax, Table IV) and
they were in the 10 mM range with the standard therapeutic
once-daily dosage of 1500 mg glucosamine sulfate; the
median Css, max at this dose was actually 9.92 mM
(1777.6 ng/ml). Thereafter, the plasma concentrations of
glucosamine slowly decreased and were still measurable
and consistently above baseline levels in the last samples
collected 48 h after dosing in all subjects at all doses. This
Table III
Mean (GSD) plasma concentrations of glucosamine at baseline,
before the second and third drug administration (Cmin, day 2 and Cmin,
day 3) and 24 h after the third and last administration (Cmin, day 4)
Administered dose
750 mg 1500 mg 3000 mg
Baseline (ng/ml) 61.8G 48.6 52.7G 17.7 53.8G 24.6
Cmin, day 2 (ng/ml) 166.9G 66.2* 185.8G 41.4* 182.2G 72.7*
Cmin, day 3 (ng/ml) 210.1G 86.3 245.7G 58.9 267.4G 70.9
Cmin, day 4 (ng/ml) 225.6G 85.0 277.3G 67.5 308.7G 97.9
*P! 0.05 vs Cmin, day 3 and P! 0.01 vs Cmin, day 4. There were
no signiﬁcant differences between Cmin, day 3 and Cmin, day 4.
1045Osteoarthritis and Cartilage Vol. 13, No. 12precluded an unequivocal estimation of the terminal phase
of the plasma concentration vs time proﬁle from which the
elimination half-life is calculated. For this reason, this
parameter could be only tentatively estimated based on
the time to reach the steady state and therefore resulted to
be on average 15 h.
Further visual inspection of the plasma concentration vs
time proﬁles of glucosamine at all doses and in all the
subjects, showed that, after a rapid rise during the
absorption phase, the plasma concentrations decreased
in a multi-exponential fashion (i.e., the plasma concen-
trations decreased rapidly soon after Tmax and then
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Fig. 1. Mean glucosamine plasma concentration vs time proﬁles at
steady state after repeated once-daily doses of glucosamine sulfate
750, 1500 and 3000 mg (nZ 12 for each dose level). Concen-
trations are baseline-subtracted and expressed as ng/ml (panel A)
or mM (panel B). Bars represent standard deviations.decreased at a slower pace from 10 h post-dosing onward).
This indicates a signiﬁcant distribution of the drug into
extravascular compartments.
Analysis of the pharmacokinetic parameters reported in
Table IV shows that although mean peak concentrations at
steady state (Css, max) apparently increase with increasing
doses, they are linear only within the 750e1500 mg dose
range, while they deviate from linearity at 3000 mg, whose
dose-normalised Css, max value was different from that
observed after the lowest dose (P! 0.05). This deviation
from linearity with the highest dose was even more evident
for the extent of bioavailability, represented by the AUCss
and AUCt values. In fact, the dose-normalised values for the
3000 mg dose were both signiﬁcantly lower than the
corresponding values calculated at the dose of 750 mg
(P! 0.01). In addition, the AUCt also differed signiﬁcantly
from the corresponding value calculated at the dose of
1500 mg (P! 0.05). This indicates that the increase in the
plasma concentrations of glucosamine observed at
the dose of 3000 mg was less than proportional based on
the dose increase. The evaluation of any possible carryover
effect was included as a factor in the statistical test utilised
for the comparison of the pharmacokinetic parameters
across doses (GLM-ANOVA). The test did not detect any
carryover effect. These results and the lack of any
signiﬁcant difference between the baseline glucosamine
plasma concentrations in the three study periods, indicated
that the washout period observed between each period (at
least 5 days) was sufﬁcient to exclude any carryover effect.
Individual baseline-subtracted plasma concentration vs
time proﬁles (Fig. 2) clearly suggest lower concentrations
with higher variability after the 750 mg dose compared with
the standard 1500 mg dose, that provided sustained
concentrations in the 10 mM range in most of the subjects.
Further doubling the dose to 3000 mg did not provide
further apparent advantage, perhaps with the exception of
more consistent concentrations in the 10 mM range in all
subjects. Glucosamine average plasma concentrations
24 h after administration were still over 5-fold higher than
mean baseline concentrations with all doses.
There were no statistically signiﬁcant gender differences
in pharmacokinetics parameters at any dose level (data not
shown). There were no safety issues during or after
treatment with any of the tested doses.
Discussion
To our knowledge, this is the ﬁrst study describing the
bioavailability and pharmacokinetics of glucosamine in
humans. This study was performed after repeated oral
doses of the patented crystalline glucosamine sulfateTable IV
Glucosamine pharmacokinetic parameters at steady state for all tested doses of glucosamine sulfate
Administered dose
750 mg 1500 mg 3000 mg
Css,max (ng/ml) 1069.2G 675.3 1601.9G 424.9 2503.1G 1835.3y
Tmax* (h) 3 (0.5e6) 3 (1.5e4) 4 (3e4)
AUCss (ngh/ml) 9697.0G 4215 14,564G 4138 22,095G 6984z
AUCt (ngh/ml) 14,323G 5582 20,216G 5021 27,991G 8035zx
Data are meanG SD, except *median and range.
yP! 0.05 vs 750 mg when dose-normalised.
zP! 0.01 vs 750 mg when dose-normalised.
xP! 0.05 vs 1500 mg when dose-normalised.
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Fig. 2. Individual glucosamine plasma concentration vs time proﬁles at steady state within a dosing interval after repeated once-daily doses of
glucosamine sulfate 750, 1500 and 3000 mg (nZ 12 for each dose level). Concentrations are baseline-subtracted and expressed in ng/ml.
Horizontal lines indicate mean endogenous plasma concentrations at baseline.formulation shown to be effective in OA pivotal clinical
trials4,5 and indicated that glucosamine is available to the
systemic circulation.
In addition, the low LOQ of the developed LCeMS/MS
method allowed to detect and quantify the endogenous
glucosamine levels in plasma. Previous animal studies
failed to detect circulating endogenous glucosamine: this
might be due to the poor sensitivity of the bioanalytical
methods19e21 and/or to species differences22. Endogenous
glucosamine circulated in human plasma at concentrations
ranging from as low as 10 to as high as 200 ng/ml. The
endogenous concentrations varied considerably between
individuals (high inter-subject variability), especially be-
tween women, but they were rather consistent within
individuals (low intra-subject variability, although with
a slight trend for some degree of variability again within
women). This might be of pathophysiological relevance for
future studies in diseased subjects. Given the role of
glucosamine in the biology of the joint10 and its therapeutic
effects1e5, further studies are warranted to investigate
possible correlations between endogenous levels and
articular disorders, with particular regard to OA, and
possible intrinsic sources of variability (e.g., disease
severity, or treatment response).
Baseline endogenous glucosamine levels were sub-
tracted in this study to allow measurement of the netincrease after exogenous administration23,24. Even though
the endogenous concentrations were low compared with
those achieved after exogenous oral administration, the
correlations between glucosamine concentrations and
therapeutic effects in patients should be made on total
plasma concentrations.
A possible limitation of our study is that it did not provide
indications of glucosamine absolute oral bioavailability as
the intravenous route of administration could not be
investigated. The absolute oral bioavailability of glucos-
amine has been estimated between 3% and 6% in
horses21,22, 12% in dogs20 and 21% in rats19 using
glucosamine hydrochloride. The data in the present study
suggest that glucosamine absolute bioavailability in man is
probably higher since the Cmax are higher and concen-
trations much more sustained compared to those found in
horses after the administration of comparable doses22.
In the present study, glucosamine was rapidly absorbed
and bioavailable at steady state. Glucosamine plasma
concentrations increased on average over 30-folds from
baseline after repeated oral administrations of the standard
1500 mg once-a-day dose of glucosamine sulfate and
reached a maximum in the 10 mM range.
Glucosamine is preferentially incorporated by chondro-
cytes into the components of the glycosaminoglycan chains
in the intact cartilage27, stimulates the synthesis of
1047Osteoarthritis and Cartilage Vol. 13, No. 12physiological proteoglycans28e30 and decreases the activity
of catabolic enzymes, including matrix metalloproteases
(MMP)29e31. As common in mechanistic studies, most of
the in vitro experiments used glucosamine concentrations
higher than those found in human plasma after therapeutic
doses in the present study, also because the latter were
previously unknown. However, selected in vitro models
showed that glucosamine was metabolically effective at
concentrations hundred-folds lower than the 10 mM average
plasma peak found here30. On the other hand, it was
recently suggested that glucosamine was not able to
stimulate glycosaminoglycan synthesis at concentrations
below 1 mM32. Whatever the concentration needed, it is
unlikely that the possible metabolic effects of glucosamine
and especially the mere incorporation in glycosaminogly-
cans are able to fully explain the pattern of effects shown in
clinical trials. In particular, even though a metabolic
hypothesis might be attractive to support the putative joint
structure-modifying effects observed after long-term treat-
ments4,5, it could not readily explain the short-term1,33,34
and long-term2e5 symptom-modifying effects, which have
been indicated as being of major clinical relevance35,36.
A unifying hypothesis has been recently proposed and
related to glucosamine-induced reversal of the pro-inﬂam-
matory and joint-degenerating effects of interleukin-1
(IL-1)31,37,38, via an inhibitory effect on the IL-1 intracellular
signalling cascade and speciﬁcally by the reduction in the
activation of the transcription factor nuclear factor-kappa B
(NF-KB)39,40. Effects connected with NF-kB decreased
activation such as chondrocyte-speciﬁc scavenging ef-
fects39, are evident already at concentrations of 10 mM41.
Moreover, IL-1-induced prostaglandin E2 release from
cartilage explants and cytokine-induced gene expression
of MMP-13 and aggrecanase 1 and 2 have been recently
shown to be inhibited already at 5 mg/ml glucosamine42,43,
i.e., a concentration only slightly above the range described
in the present study.
An alternative hypothesis has been recently put forward
by Laverty and coworkers22, who suggested looking at
altered metabolic activities in tissues where extracellular
glucosamine concentrations should be higher, including the
intestine, liver and kidney, and that might modulate the
compound anti-arthritic effects.
The pharmacokinetic proﬁle of glucosamine suggests
a distribution between the vascular and extravascular
compartments, as shown by the multi-exponential decay
of plasma concentrationetime proﬁles. Previous stud-
ies8,44,45 indeed showed that orally administered radio-
labelled glucosamine distributes to several organs and
selectively to the joint and the articular cartilage. It is
therefore conceivable that glucosamine concentrations at
the articular site of action may be higher than those found in
plasma. While recently published results obtained in horses
have indicated that the synovial concentrations of glucos-
amine were, on average, 10% of those observed in
serum22, preliminary data we are obtaining in knee OA
patients suggest that plasma and synovial ﬂuid levels are
equal, i.e., in a 1:1 relationship (Persiani et al., unpublished
observations) and deserve further investigation.
In addition, it should be taken into account that
glucosamine sulfate is continuously administered to pa-
tients for months or years and extrapolation of clinical
effects solely based on concentrations may be misleading,
as it does not consider the duration of exposure, i.e., the
product of concentration and time.
The elimination half-life of glucosamine could not be
calculated in the present study due to the sustained plasmaconcentrations observed. However, the pharmacokinetics
of glucosamine were at steady state after three consecutive
daily oral administrations. Since after a constant dose and
dosing interval, steady state conditions are reached after
ﬁve elimination half-lives26, the latter was tentatively
estimated to be approximately 15 h for glucosamine in this
study. These ﬁndings support the once-daily oral dosages
of glucosamine sulfate used here and in pivotal efﬁcacy and
safety trials4,5.
The ﬁnding that the plasma concentrations of glucos-
amine persisted above baseline for 48 h after dosing was
taken into consideration when assessing if the washout
period between treatments was sufﬁcient. Indeed, it
appears that the levels had returned to baseline virtually
in all subjects at the start of each treatment period,
occurring at least 5 days post-dosing. This was also
conﬁrmed by the absence of any statistically signiﬁcant
difference between the baseline glucosamine concentra-
tions in each of the three study periods and by the lack of
any carryover effect during the comparison of the pharma-
cokinetic parameters across doses.
Glucosamine pharmacokinetics appeared to be linear,
i.e., dose-proportional, up to the glucosamine sulfate
standard dose of 1500 mg once-a-day. Half the recom-
mended dose (750 mg) provided approximately half plasma
levels and may have proportionally lower pharmacological
and clinical effects, further challenged by a much greater
variability than with the standard dose. Higher doses, e.g.,
the 3000 mg tested here, deviated from linearity for both the
rate and the extent of bioavailability, in that this dose
increase failed to produce proportionally higher increases in
maximum concentrations and area under the concentration
vs time curve. This may be due to a saturation of the
absorption process, as can be also evinced from the higher
Tmax values observed at this dose. This implies that doses
higher than 1500 mg glucosamine sulfate, by producing
proportionally lower plasma concentrationetime proﬁles
may not be clinically worth.
The present study has been conducted using the once-a-
day soluble powder formulation of crystalline glucosamine
sulfate used in pivotal clinical trials4,5, which is a prescription
drug in most European countries. Transfer of the efﬁcacy
and safety data obtained with this substance and formula-
tion to common dietary supplements, has already been
discouraged4,5,35. In fact, these uncontrolled formulations
often have a much lower glucosamine content than reported
in their label claims and are thus commonly underdosed12.
In addition, there is currently no clinical justiﬁcation to use
different glucosamine compounds or even glucosamine
salts, e.g., hydrochloride, as pivotal trials failed to show the
same beneﬁt3,13. While some authors suggested that
sulfate levels increased after administration of glucosamine
sulfate and may signiﬁcantly contribute to its effects46,47,
pharmacokinetic considerations should also be taken into
account. In fact, the bioavailability of different salts of the
same compound may vary signiﬁcantly, especially when
they are included in solid oral formulations whose compar-
ative dissolution proﬁle and interaction with excipients are
unknown48. The question of the unit dose is also relevant. In
fact, we have clearly shown that unit doses lower than
1500 mg give proportionally lower plasma levels: therefore,
appropriate pharmacokinetic and pharmacological studies
should be performed before fractioning the 1500 mg once-
a-day standard dose4,5 into smaller and more frequent
doses is justiﬁed. Such fractioning is done in some currently
ongoing trials49, after recent studies failed to show the
clinical relevance of this approach13e16. In addition,
1048 S. Persiani et al.: Oral glucosamine bioavailability in manglucosamine sulfate is not stable as such and should be
adequately stabilised, as achieved by a patented process50
for the formulation used here and in the majority of trials3e5.
Doubts in this respect may explain the negative ﬁndings
obtained in short-term clinical studies of previously untested
glucosamine sulfate formulations14e16, besides their many
confounders in terms of sample size and characteristics,
disease severity, use of concomitant medications and other
problematic study design features3,17.
In conclusion, we have described the pharmacokinetic
proﬁle of glucosamine after administration of crystalline
glucosamine sulfate in man. Our ﬁndings indicate that the
drug is orally bioavailable at concentrations that are in line
with those found to be effective in selected in vitro models
that may explain the favourable clinical results in OA. Future
studies should compare the bioavailability of this patented
formulation with that of other glucosamine salts, derivatives,
formulations, or dose regimens.
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